Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression

References

• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Bailey P, Chang DK, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207.
   PubMed Web of Science ®Google Scholar
• Strobel O, Neoptolemos J, Jager D, et al. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26.
   PubMed Web of Science ®Google Scholar
• He C, Zhang Y, Cai Z, et al. Nomogram to predict cancer-specific survival in patients with pancreatic acinar cell carcinoma: a competing risk analysis. J Cancer. 2018;9(22):4117–4127.
   PubMed Web of Science ®Google Scholar
• Tani T, Kawashima I, Mita K, et al. Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic Acids Res. 1990;18(6):1631.
   PubMed Web of Science ®Google Scholar
• Lin B, Zhou X, Lin S, et al. Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma. J Mol Med. 2017;95(11):1237–1249.
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Okpukpara C, Danaee H, et al. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Mol Carcinog. 2005;44(2):146–150.
   PubMed Web of Science ®Google Scholar
• Ma R, Ye X, Cheng H, et al. PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2015;137(3):546–552.
   PubMed Web of Science ®Google Scholar
• Qian L, Gao X, Huang H, et al. PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast. Oncotarget. 2017;8(13):21444–21453.
   PubMedGoogle Scholar
• Jiang G, Cao F, Ren G, et al. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut. 2010;59(11):1535–1544.
   PubMed Web of Science ®Google Scholar
• Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–442.
   PubMed Web of Science ®Google Scholar
• Nigro JM, Cho KR, Fearon ER, et al. Scrambled exons. Cell. 1991;64(3):607–613.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Hansen TB, Veno MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–565.
   PubMed Web of Science ®Google Scholar
• Qiu LP, Wu YH, Yu XF, et al. The emerging role of circular RNAs in hepatocellular carcinoma. J Cancer. 2018;9(9):1548–1559.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Du Y, Yang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17(1):79.
   PubMed Web of Science ®Google Scholar
• Zeng K, Chen X, Xu M, et al. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018;9(4):417.
   PubMed Web of Science ®Google Scholar
• Hu C, Wang Y, Li A, et al. Overexpressed circ_0067934 acts as an oncogene to facilitate cervical cancer progression via the miR-545/EIF3C axis. J Cell Physiol. 2018;234(6):9225–9232.
   PubMed Web of Science ®Google Scholar
• Han D, Li J, Wang H, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66(4):1151–1164.
   PubMed Web of Science ®Google Scholar
• Verduci L, Strano S, Yarden Y, et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol Oncol. 2019;13(4):669–680.
   PubMed Web of Science ®Google Scholar
• Hockla A, Miller E, Salameh MA, et al. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res. 2012;10(12):1555–1566.
   PubMed Web of Science ®Google Scholar
• Radisky ES. PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine. Asian J Androl. 2013;15(4):439–440.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram KH, Soleymani FS, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Dong X, He X, Guan A, et al. Long non-coding RNA Hotair promotes gastric cancer progression via miR-217-GPC5 axis. Life Sci. 2019;217:271–282.
   PubMed Web of Science ®Google Scholar
• Wang B, Qu XL, Liu J, et al. HOTAIR promotes osteosarcoma development by sponging miR-217 and targeting ZEB1. J Cell Physiol. 2019;234(5):6173–6181.
   PubMed Web of Science ®Google Scholar
• Wang H, Ke J, Guo Q, et al. Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular carcinoma cells through miR-217/MAPK1 axis. J Cell Mol Med. 2018;22(12):5862–5876.
   PubMed Web of Science ®Google Scholar
• Ding J, Yeh CR, Sun Y, et al. Estrogen receptor beta promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. Oncogene. 2018;37(37):5037–5053.
   PubMed Web of Science ®Google Scholar
• Hong Q, Li O, Zheng W, et al. LncRNA HOTAIR regulates HIF-1alpha/AXL signaling through inhibition of miR-217 in renal cell carcinoma. Cell Death Dis. 2017;8(5):e2772.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Haemmig S, Baumgartner U, et al. MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. Mod Pathol. 2017;30(8):1116–1125.
   PubMed Web of Science ®Google Scholar
• Yan J, Wu G, Chen J, et al. Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. CBM. 2018;22(1):73–78.
   Web of Science ®Google Scholar
• Zhou W, Song F, Wu Q, et al. MiR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5. PLoS One. 2017;12:e176395.
   PubMed Web of Science ®Google Scholar
• Shang Q, Yang Z, Jia R, et al. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18(1):6.
   PubMed Web of Science ®Google Scholar
• Abdollahzadeh R, Daraei A, Mansoori Y, et al. Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmarks of breast cancer. J Cell Physiol. 2018;234(7):10080–10100.
   PubMed Web of Science ®Google Scholar